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Multiple antigen peptide systems (MAPs) 1 for peptide-based vaccines were de-
signed by one of us to overcome the ambiguity and requirement of conjugation to
a protein carrier by synthetic peptides (1, 2) . The MAP system consists of an oligo-
meric branching lysine core, usually comprised of seven lysines, and eight dendritic
arms of peptides containing antigenic epitopes . Since each arm of peptidemay con-
sist of 10 to more than 20 amino acids, the overall appearance of theMAP system
is of a macromolecule with a high density of surface peptide antigen and a molec-
ular weight exceeding 10,000, surrounding a lysine scaffolding core of molecular
weight of <800 .
The immunogenicity of monoepitope MAPs has been tested in animals (1, 2) .
All model MAPs elicited high-titered antisera, most ofwhich recognized the cog-
nate protein fromwhich the epitopes were derived . However, some issues concerning
the possible use of the MAP system for production of vaccines were not resolved .
One important remaining question is whether the MAPs can be engineered to con-
tain not only B cell epitopes but also functionalT cell epitopes, selected from protein
molecules that are candidates for development of subunit vaccines . In addition, the
effect of the stoichiometry, orientation, and arrangement of the B and T epitopes
on the immunogenicity of the MAPs has not been determined .
To study these problems we prepared 10 MAP models containing T and B epi-
topes of the circurnsporozoite (CS) protein of the rodent malaria parasite, Plasmo-
dium berghei. The immunodominant B cell epitope of theP . bergheiCS protein is con-
tained within its repeat domain and can be represented by a 16-residue peptide
(PPPNPND)z (3, 4) . Monoclonal and polyclonal antibodies against the repeat do-
mains of the CS protein neutralize in vitro and in vivo the infectivity of malaria
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sporozoites (reviewed in reference 5). Recently, several T helper epitopes ofthe P . berghei
CS protein have been identified, thus providing the opportunity not only to develop
di-epitope MAPs, but also to test their efficacy as vaccines in a well-characterized
rodent malaria model. One of these T helper epitopes, between residues 265 and
276 (KQIRDSITEEWS), was selected for inclusion in the di-epitope MAPs because
it was recognized by several inbred strains of mice and particularly because it dis-
played helper activity in vivo (6).
Materials and Methods
Synthesis and Characterization ofMAPs.
￿
The monomeric BT peptide was synthesized as de-
scribed (6) by a stepwise solid-phase peptide synthesis method of Merrifield (7). MAPS were
synthesized as described, on a tertbutoxycarbonyl (Boc)-Ala-Pam resin with a low loading
(0.1 mmol/g of resin) (1). In the MAP models containing four copies of the peptide antigens
[T-(4), B-(4), BT(4), and TB-(4)], the core was synthesized with only three lysines prepared
from branching with two levels ofBoc-Lys(Boc), while in the MAP models containing eight
copies of the antigens [T(8), B-(8), BT-(8), and TB-(8)], the core was synthesized with seven
lysines prepared from branching with three levels of Boc-Lys(Boc). In the MAP models con-
taining eight copies of B or T antigens and one copy of T or B antigen [B-(8)-T, T(8)-B],
the B or T antigen was first synthesized linearly on the Boc-Ala-Pam resin and then branched
with three levels of lysine to give the subsequenteight copies ofT or B antigens. All peptides
and MAPS were cleaved from the resin supports by the low/high HF procedure (8) to mini-
mize side reactions, and the peptides were extracted from the resin with, and extensively
dialyzed in, 8 M urea in 0.1 M Tris/HCI buffer, pH 8.0. All MAP products were character-
ized by high-performance gel chromatography. Amino acid analysis gave satisfactory results
that agreed with the expected composition.
Immune Responses ofMAPs.
￿
Groups of five mice of the H-2a haplotype (A/J strain) were
injected with 50 Kg i.p. of a given MAP, or a mixture of MAPs [T(8) + B-(8)], emulsified
in CFA on day 0, and boosted with 50,ug of the same antigen in IFA on day 21. Sera were
collected 21 d later. Sera were pooled and antibody titers were determinedby an immunoradio-
metric assay usinga recombinant CS protein as antigen or by indirect immunofluorescence
(IFA) using glutaraldehyde-fixed sporozoites as antigen. The titers were expressed as the
reciprocal of the highest positive serum dilution.
Results and Discussion
The 10 MAP models (Fig. 1) included tandemly connecting B and T epitopes,
with four or eight peptide antigen arms [models BT(4), and BT(8)], and similar
models in which the orientation of the B and T epitopes was reversed [models TB-
(4), TB-(8)]. To test the importance ofthe stoichiometry ofthe B and T cell epitopes,
model B-(8)-T contained eight copies of the B epitope and only one copy of the T
epitope, while model T(8)-B contained eight copies of the T epitope and only one
copy of the B epitope. As controls, we prepared four different models of MAPs con-
taining either B or T cell epitopes alone. Two of the control models [T(4), B-(4)]
contained four copies of either B or T epitopes, and the other two [T(8), B-(8)] con-
tained eight copies of either epitope. For comparison, a monomeric peptide [BT]
containing only one copy each of the B and T epitopes was prepared.
To assay for the presence of the B epitope in the MAPs, we used the 3D11 mono-
clonal antibody (9) raised against P . berghei sporozoites and which reacts with the
16 amino acid B epitope (10). All MAPs containing the B epitopes were strong in-
hibitors of the binding of radiolabeled 3D11 to sporozoites immobilized in wells of
microtiter plates. 50% inhibition ofbinding was observed at MAPs concentrationsTAM ET AL .
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FIGURE 1 .
￿
Schematic represen-
tation ofthe structure ofthe CS
protein ofP . bergheiofthe mono-
meric form of a peptide con-
taining tandem B andT cell epi-
topes and of 10 MAP models
(see text for explanation),
of 10 -t° to 10-t3 M, while the same degree of inhibition required -10-sM of the
monomeric peptideBT (datanot shown) . TheMAN containing only theTepitope
were noninhibitory . These results indicated that the B epitopes in the MAPs func-
tioned as antigens .
Wehad earlier shown that immunization with theP . bergheiB epitope alone, either
as a monomer or as an octameric MAP, did not elicit antibody responses in A/J
and several other inbred strains of mice (6) . To test for the capacity of the newly
designedMAPantigens to elicit the production ofantibodies to this B epitope, groups
of five A/J mice were immunized with each of the 10 models ofMAPs . Additional
control groups were immunized with a BT monomer, or with a mixture of equal
amounts of B-(8) andT I(8) . The pooled sera from each group of animals were as-
sayed fortheir reactivities with the recombinant CS protein by immunoradiometric302 MULTIPLE ANTIGEN PEPTIDE SYSTEM IN PEPTIDE-BASED VACCINES
assay(IRMA) and with glutaraldehyde-fixed sporozoites by indirect immunofluores-
cence assay (IFA).
The primary antibody responses, measured 3 wk after the first antigen dose, showed
that the MAPS that contained equimolar T and B epitopes, linked in tandem, were
highly immunogenic. The best immunogen, BT(4), produced serum antibody levels
that were detectable at dilutions greater than 105. The secondary antibody responses
observed 21 d (Fig. 2) and 34 d after administration of a second dose of the MAPS
were significantly higher, but the ranking order of immunogenicity was similar to
that observed in the primary responses. The serum titers of mice injected with BT
(4), were greater than 4 x 105 , while the other three di-epitope MAPs containing
equimolar T and B peptides, elicited titers between 105 and 4 x 105. The animals
immunized with the mono-epitope B-(4) and B-(8) MAPS did not respond. There
was a poor antibody response to T(8)-B, B-(8)-T, T(4), and T(8). TB monomers
or a mixture of equimolar amounts of B-(8) and T-(8) failed to elicit an antibody
response. Thus, a covalent high molecular weight structure containing multiple copies
of tandemly arranged B and T epitopes was required for good immunogenicity.
The IFA titers of the sera 34 d after the booster injection are shown in Table I.
The BT(4)-injected mice had IFA titers of 1.28 x 105 against sporozoites. These
titers are at least 10 timeshigher than thoseusually found in the serum of mice hyperim-
munized with irradiated sporozoites. Immunization of A/J mice with similar doses
of recombinant P. bergheiCS protein incorporated in CFA, encompassing aminoacids
81-277, resulted in much lower IFA titers (2 x 103) (6). It should be pointed out
that although the present results were obtained with the P. berghei MAPS incorpo-
rated in CFA, high antibody titers were elicited with other MAPs when the adjuvant
was alum, or even in the absence of adjuvant (in preparation). A plausible explana-
tion for the greater immunogenicity of the MAPs may be that they contain a high
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FIGURE 2. Secondary antibody responses of
groups of mice immunized with different MAP
models.TAM ET AL.
￿
303
TABLE I
Protective Efficacy of Different MAP Models in Mice
Challenged with 2, 000 P. berghei Sporozoites
Titer determined by IFA using glutaraldehyde-fixed sporozoites, 34 d after
the booster injection of antigen.
: Mice were challenged by intravenous inoculations of 2,000 sporozoites 35 d
after the booster injection. Peripheral blood smears were examined daily for
parasitized erythrocytes. Protection is defined as absence ofparasites from day
3 to 12 after challenge.
density and multiple copies of peptide antigens. In the recombinant CS protein,
there are single copies of the T epitope and multiple B epitopes. Such an arrange-
ment was simulated in the design of the B-(8)-T model that was apoor immunogen.
In addition, as reported for other antigens, the CS protein may contain epitopes
that suppress antibody responses (11).
Because the tandemly connected B and T cell epitopes in the MAP are relatively
long, it is conceivable that the steric interactions between branches, and theepitope
orientations of MAPS, may influence their immunogenicity. For example, the less
bulky model BT(4) produced N50-fold higher antibody titers than BT(8). How-
ever, there was little difference in immune response between the reversely oriented
models TB-(4) and TB-(8). Although the present results indicate that there is no
advantage to increasing the number of MAP branches from 4 to 8, the effects on
the immune response of the number of the B and T epitopes in the MAP models
may be sequence dependent, and may require optimization in agiven experimental
system. It is noteworthy that the B cell epitope tested in this study is exceptionally
rich in proline(50%), whiletheT cell epitopehas astrong propensity for amphipathic
helix formation.
The efficacy of the MAPS as vaccines was evaluated by intravenous challenge of
the immunized mice with 2,000P . berghei sporozoites 35 d afterthe booster injection.
80% of the mice immunized with BT(4) were protected, and in the groups of mice
immunized with the other three di-epitopes MAPS, there was 50-60% protection
(Table I). The levels of antibodies to sporozoites (IFA) in the vaccinated mice cor-
related well with the degree of protection. No protection was observed in mice im-
munized with the mono-epitope MAPS or the monomer BT
Although theIFAtiters ofmice hyperimmunized with irradiated P . berghei sporozoites
are much lower than those after immunization with the di-epitope MAPs, the mice
Immunogen
Antisporozoite
(IFA titer x 10-3)'
Number:
protected/challenged Protection
BT-(4) 128 4/5 80
TB-(4) 32 3/5 60
TB-(8) 32 3/5 60
BT-(8) 8 2/4 50
T-(4) <0.2 0/4 0
B-(4) <0.2 0/5 0
B-(8) <0.2 0/5 0
BT monomer <0.2 0/5 0
No immunogen - 0/5 0304
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resist challenge with much higher doses ofsporozoites, underscoring the importance
of T cell effector mechanisms in protection (12). Early experiments had shown that
Ft-suppressed mice, which do not make antibodies, can be effectively vaccinated with
irradiated sporozoites (13). In this model of immunization, CD8' cytotoxic T cells
are required for protection (14, 15), and their target is most likely the liver stage
of the parasite (16, 17). In fact, passive transfer to naive mice of CD8' cloned T
cells recognizing an epitope of the CS protein of P . berghei can confer a high degree
of protection against challenge with sporozoites (18).
While considerable progress has been made in understanding the mechanisms
of protection in murine malaria models, the relative importance of serum antibodies
and effector T cells in mediating protection against human malaria sporozoites has
not been established (5, 19). Two P.falciparum malariavaccines have undergone human
trials. One was a recombinant fusion protein containing multiple copies of NANP
(20), the B epitope of the P . falciparum CS protein (21), and the other was asynthetic
vaccine consisting of (NANP)3 coupled to a tetanus toxoid carrier (22). In both
trials, one out of six and one out of three volunteers were protected, although the
serum levels of antisporozoite antibodies were low. The frequency and magnitude
of the antibody response in the volunteers receiving the synthetic vaccine increased
with the dose of the conjugate. Unfortunately, however, the peptide vaccine dose
could not be raised due to the toxicity ofthe tetanus toxoid carrier. It is also conceiv-
able that the immune response to the peptide was suppressed because thevolunteers
had been previously vaccinated with tetanus toxoid (23). These two problems, car-
rier toxicity and epitopic suppression, may severely limit the effectiveness of this
synthetic malaria vaccine and of other similarly designed vaccines. Both obstacles
can be overcome by di-epitope MAPS. In addition, as shown here, these chemically
unambiguous structures can be highly immunogenic and engineered to contain at
leasttwo and perhapsseveral different functional B andT epitopes. MAPs maythere-
fore serve as a basis fordeveloping subunitvaccines for diseases in which circulating
antibodies play a role in protection.
Summary
We show here an effective andnovel approach to engineer peptide-based vaccines
usingachemically definedsystem, knownas multiple peptideantigen systems(MAPs),
to protect an inbred mouse strain from infection against rodent malaria. 10 mono-
and di-epitope MAP models containing different arrangements and stoichiometry
of functional B and/or T helper cell epitopes from the circumsporozoite protein of
Plasmodium berghei were used to immunize A/J mice. While these mice did not re-
spond to the mono-epitope MAP bearing only the B or T epitope, very high titers
of antibody and protective immunity against sporozoite challenge were elicited by
di-epitope MAPs, particularly those with the B andT epitopes in tandem and present
in equimolaramounts. These results, obtained in awell-defined rodent malariamodel,
indicate that MAPs may overcome some of the difficulties in the development of
synthetic vaccines, not only for malaria but also for other infectious diseases.
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